Official ESCRS | European Society of Cataract & Refractive Surgeons
Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert


Search Title by author or title

PanOptix trifocal implants: preliminary results for 20 patients

Poster Details

First Author: P.Gohier FRANCE

Co Author(s):    M. Pepin   P. Gohier                 

Abstract Details


Twenty patients were fitted with Panoptix trifocal implants (ALCON) in the Ophthalmology Department of Angers University Hospital between April 2016 and February 2017. The aim of this preliminary observational study is to determine the initial results in terms of visual acuity, patient satisfaction, and potential side effects.


Sophie Assad, Maxime Pepin, Dr Philippe GohierOphtalmology Departement, CHU of Angers, France


It is a retrospective observational study involving 20 patients suffering from a cataract who were fitted with a Panoptix trifocal implant between April 2016 and February 2017. Each patient consented to the implant after being fully informed and after ruling out the following contraindications: corneal astigmatism >0.75 D, an associated eye condition,requiring patients . The lens power calculation was performed using IOL master and several formulas, and adapted to each patient�â�€�™s emmetropia. Assessment was made on the postoperative residual ametropia for far and near vision, patient satisfaction, and side effects reported within one month of the surgery.


Thirty-six eyes were implanted in 15 women and 5 men. The average age of patients was 68.6 years. Average postoperative far visual acuity was 0.32 � 0.396 and near visual acuity was 0.25 � 0.214, both according to the LogMAR chart. Thirteen patients did not require corrective lenses following the surgery, feeling comfortable with their far, intermediary and near vision. Seven patients required an additional corection to optimise their visual acuity, with an average of an additional �.3 dioptres. Nineteen patients were very satisfied after their implant. Three patients described halos within 1 month of the surgery.


This preliminary study demonstrates the benefits of Panoptix in terms of the effects on visual acuity and the small number of side effects reported by patients, who generally adapt quickly to the implant. Improving the precision of the lens power calculation should improve the results even further.

Financial Disclosure:


Back to Poster listing